Diabetic Neuropathy: A Guide to Pain Management.
Level 5 - mechanism / opinion, no new human data
Narrative review of existing management strategies without systematic review or meta-analysis methodology.
PubMed 38967712 · doi:10.1007/s11916-024-01293-9
What was done
This narrative review synthesizes the epidemiology, pathogenesis, preventative care, and current pharmacological and nonpharmacological treatment strategies for painful diabetic neuropathy.
What was found
Diabetic neuropathy affects up to 50% of diabetes mellitus patients during their lifetime, and up to 69% receive pharmacological therapy for pain. The review identifies four FDA-approved drugs (pregabalin, duloxetine, tapentadol, and 8% capsaicin patch) and notes potential utility for nonpharmacological modalities like spinal cord stimulation and transcutaneous electrical nerve stimulation. No specific numerical efficacy comparisons or effect sizes are provided in the abstract.
Why it matters
It provides a clinically oriented summary of approved and emerging pain management options for a common complication that lacks disease-modifying therapies.
Limits
The paper is a narrative review without systematic search criteria, meta-analytic pooling, or new patient data. The abstract provides no primary data, effect sizes, or safety comparisons.
Cited by
- supports Diabetic neuropathy occurs in more than 50% of diabetics at some point during their lifetime.
- supports Approximately 50% of people with diabetes develop neuropathy.